Cases & Deals

Celgene negotiates drug discovery and license agreement with PTC Therapeutics

Clients Celgene Corporation

Jones Day negotiated a $20 million drug discovery and license agreement between Celgene Corporation and PTC Therapeutics. Under the terms of the agreement, Celgene received exclusive development rights to orally bioavailable small molecules for two undisclosed oncology targets and was granted access to the Gene Expression Modulation by Small Molecules (GEMS) screening technology. The transaction also included a stock purchase agreement.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.